For these reasons, synovial inflammation and changes associated with specific OA phenotypes are considered an appropriate therapeutic target, but trials using anti-TNF [22] and anti-IL-1 have shown only weak, inconsistent results in terms of pain reduction, MRI synovitis scores, and structural progression in patients with joint inflammation associated with OA. Here, TNF is linked to inflammatory response.